For Patients For Physicians Treatments and Procedures News Career Opportunities Online Appointment Request Download and Print Patient Forms Referring Physician Form
Text Resize

Research and News from the Retina Group of Florida

Our ophthalmic research, clinical trials, and a fully staffed research division are key components of Retina Group of Florida’s dedication to finding treatment options for patients.

Retina Group of Florida places a high priority on its commitment to the advancement of medical research. Through the Retina Research Foundation, a fully staffed division of Retina Group of Florida, we work with scientists at the Foundation Fighting Blindness, National Eye Institute, and other academic institutions to find and test new treatments for eye disease. Our highly skilled physicians are involved in medical studies concerning macular degeneration, diabetic retinopathy, vascular occlusion of the retina, new surgical techniques, and other diseases of the eye. We periodically announce the latest research findings to our patients at special seminars.

Clinical trials are a very significant part of our research because they allow us to bring potential treatment options to you long before they are available to the general population. We currently are involved in more than a dozen clinical trials, including some that may restore sight for some people with macular degeneration and diabetic retinopathy. Retina Group of Florida is a prominent member of the Diabetic Retinopathy Clinical Network, a select group of physicians conducting clinical trials in partnership with the National Eye Institute. Your doctor will know if you are a candidate for any of these exciting new discoveries.

Some of our physicians also serve as clinical faculty members of the University of Miami Miller School of  Medicine and Florida Atlantic University School of Medicine and principal investigators in ground-breaking advances in the treatment of eye diseases, in addition to their full-time medical practices. This dedication to advanced medical science is just part of our vision for the future in retinal health care.

Retina Group of Florida is currently involved in multiple national clinical trials of the latest medical and surgical advances in retinal disease, including:

Wet Macular Degeneration

LADDER is a trial studying the ranibizumab Port Delivery System for Sustained Delivery of ranibizumab in Patients with Subfoveal Neovascular Age‐Related Macular Degeneration

Capella is a Phase 2 study of a co-formulation anti-pdgf/anti-veg-f intravitreal injection compared to Eylea in patients with Treatment Naïve Neovascular Age-Related Macular Degeneration.

OPH1004 is a phase 3 study comparing an investigational intravitreal anti-PDGF aptamer, Fovista, combined with either bevacizumab or aflibercept compared to bevacizumab or aflibercept monotherapy.

Dry Macular Degeneration (Geographic Atrophy)

SPECTRI is a trial studying intravitreal injections of lampalizumab, an anti-factor D antibody fragment for the treatment of geographic atrophy.

TOGA is a study that involves daily oral administration of ORACEA, a subantimicrobial dose tetracycline derivative, compared to placebo for the treatment of geographic atrophy.

Retinal Vein Occlusion

SCORE 2 trial is comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks for the treatment of macular edema secondary to CRVO. After 6 months, patients may be re-randomized to dexamethasone implant if poor response.

Upcoming Studies

Macular Degeneration

ECT Study is a Phase I study to evaluate the Intravitreal Implantation of Encapsulated Cell Technology, which provides intravitreal sustained release of soluble VEGF receptor, compared with aflibercept for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration.

Uveitis

PEACHTREE is a phase 3 trial with use of triamcinolone acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema associated with Non-Infectious Uveitis.

Diabetic Retinopathy

Panorama is a phase 3 study of IVT aflibercept injection (IAI) in patients with Diabetic Retinopathy. Patients must be treatment naïve.

READ-4 is a study to evaluate the safety of intravenous (IV) infusions of Tocilizumab in the treatment of subjects with diabetic macular edema (DME) as monotherapy and in combination with intravitreal (IVT) ranibizumab.

For more information please call our office at 954-776-6880 and ask to speak to one of the Study Coordinators.

Home Page Meet Our Physicians Our Services Make an Appointment